יתרות המזומנים של החברה: Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics (ELTX) is developing innovative cancer vaccines that activate immunity directly in the lymph nodes via the AMP system. The business is protected by patents for its AI platform and strict FDA oversight, while the change in cash levels on the GURU.Markets general chart shows that the current metric is 0.03. The company is currently focusing on the clinical validation of the efficacy of its therapies for pancreatic and colorectal cancers.
פילוחים אנליטיים ודוחות נתונים של חברת Elicio Therapeutics, Inc. (ELTX)

For the biopharmaceutical startup Elicio Therapeutics (ELTX), which is developing the Amphiphile platform, the volume of liquid assets is a critical indicator of its ability to fund costly R&D cycles. This metric aggregates cash and cash equivalents, measuring the actual runway before a new issuance round becomes necessary. By analyzing current cash holdings, an investor assesses capital management efficiency and the risk of liquidity gaps. A stable level of reserves confirms the viability of the business model during the vaccine development period.